Global Allergy Diagnostic Market Size By Type (Assay kits, Consumables), By Application (Academic Institutes, Diagnostic Laboratories), By Region, And Segment Forecasts, 2023 to 2032

The Global Allergy Diagnostic Market was valued at USD 4.9 billion in 2023 and is projected to reach USD 9.3 billion by 2031, growing at a CAGR of 8.3% during the forecast period from 2023 to 2031. The market is witnessing robust growth driven by the rising prevalence of allergic conditions globally, advancements in diagnostic technologies, and increased awareness regarding early and accurate allergy diagnosis. Allergy diagnostics play a crucial role in identifying specific allergens responsible for hypersensitivity reactions, enabling timely intervention and effective management of allergic disorders such as asthma, allergic rhinitis, eczema, and food allergies.

Drivers:

1. Increasing Prevalence of Allergic Diseases:

Globally, the incidence of allergic conditions such as asthma, hay fever, and food allergies is on the rise. This trend, exacerbated by environmental pollution and dietary changes, is fueling the demand for advanced allergy diagnostic solutions.

2. Technological Advancements in Diagnostic Tools:

Innovations such as component-resolved diagnostics (CRD), multiplex assays, and microarray platforms are enhancing test accuracy, speed, and the range of allergens detectable. These improvements are expanding diagnostic capabilities and promoting wider adoption.

3. Growing Patient Awareness and Healthcare Access:

Greater awareness among patients about allergic conditions and an increase in health insurance coverage for diagnostic procedures are contributing to market growth, especially in emerging economies.

Restraints:

1. High Cost of Allergy Testing Procedures:

The cost of sophisticated allergy diagnostic tests, including immunoassays and molecular testing, can be high, limiting their accessibility in low- and middle-income countries.

2. Lack of Standardization Across Laboratories:

Variability in testing procedures, allergen extracts, and interpretation methods across diagnostic labs can affect test reliability, posing a challenge to market consistency.

Opportunity:

1. Expansion into Emerging Economies:

Rapid urbanization and increasing healthcare investments in Asia-Pacific and Latin America are creating significant opportunities for allergy diagnostic providers to penetrate untapped markets.

2. Integration of AI in Diagnostics:

The integration of artificial intelligence and machine learning in allergy diagnostics offers promise for enhanced accuracy, predictive modeling, and streamlined workflows, providing a competitive edge to innovators.

Market by System Type Insights:

In 2023, the In Vivo segment, which includes skin prick tests and intradermal tests, held the largest market share due to its affordability and quick results. However, the In Vitro segment, particularly ImmunoCAP and ELISA-based tests, is projected to grow at a higher CAGR owing to its higher sensitivity and suitability for patients with skin conditions or those taking antihistamines.

Market by End-use Insights:

The Diagnostic Laboratories segment dominated the market in 2023, accounting for over 40% of the global revenue. This is attributed to the increasing outsourcing of allergy testing to specialized labs and the growing volume of tests processed daily. The Hospital segment also showed notable growth, supported by integrated diagnostic systems and rising patient footfall.

Market by Regional Insights:

North America led the global allergy diagnostic market in 2023, backed by advanced healthcare infrastructure, high prevalence of allergic conditions, and the presence of key market players. Meanwhile, Asia-Pacific is anticipated to witness the fastest growth due to rising awareness, increasing disposable incomes, and favorable government initiatives to improve allergy care services.

Competitive Scenario:

Key players operating in the Global Allergy Diagnostic Market include Thermo Fisher Scientific Inc., Danaher Corporation, Siemens Healthineers, bioMérieux SA, Stallergenes Greer, HYCOR Biomedical, R-Biopharm AG, EUROIMMUN AG, and Omega Diagnostics Group PLC. These companies are actively investing in R&D, strategic acquisitions, and global expansion initiatives.

Notable Developments:

2023: Thermo Fisher launched a next-gen ImmunoCAP platform for broader allergen profiling.

2024: bioMérieux introduced a compact, AI-integrated allergy diagnostic system targeting mid-sized labs.

2025: Siemens Healthineers announced a partnership with a major hospital network to pilot automated allergy testing suites.

Scope of Work – Global Allergy Diagnostic Market

Key Market Developments:

Thermo Fisher Scientific Inc. launched an enhanced multiplex allergy testing solution in 2023, expanding its test panel to cover rare allergens.

EUROIMMUN AG entered into a strategic agreement with Asian distributors in 2024, strengthening its regional presence in Asia-Pacific.

Stallergenes Greer introduced a home-based testing kit under FDA review in 2025 to meet growing demand for telehealth-compatible diagnostics.

FAQs:

1) What is the current market size of the Global Allergy Diagnostic Market?

The market size in 2023 is valued at USD 4.9 billion.

2) What is the major growth driver of the Global Allergy Diagnostic Market?

The increasing prevalence of allergic conditions and advancements in diagnostic technologies are key growth drivers.

3) Which is the largest region during the forecast period in the Global Allergy Diagnostic Market?

North America is the largest region due to its strong healthcare infrastructure and widespread use of advanced diagnostics.

4) Which segment accounted for the largest market share in Global Allergy Diagnostic Market?

The In Vivo segment led the market in 2023, particularly due to widespread usage of skin prick tests.

5) Who are the key market players in the Global Allergy Diagnostic Market?

Major players include Thermo Fisher Scientific Inc., Siemens Healthineers, bioMérieux SA, Danaher Corporation, and Stallergenes Greer.